DexCom Investors Get Late-December Cutoffs to Seek Lead Role in Securities Cases
Plaintiff firms cite an FDA warning letter alleging unauthorized G6/G7 sensor changes that reduced accuracy, raising safety risks.
Overview
- Dueling notices from Rosen, Kessler Topaz, Kirby McInerney and Gross urge DexCom shareholders to move for lead-plaintiff status by December 26 or December 29, 2025.
- Rosen and Kirby reference a July 26, 2024 to September 17, 2025 class period, while Gross and Kessler Topaz list January 8, 2024 to September 17, 2025.
- Complaints contend DexCom made unapproved design changes to its G6 and G7 devices and overstated reliability and enhancements while downplaying safety issues.
- DexCom disclosed receipt of an FDA warning letter on March 7, 2025, and the FDA published it on March 25, 2025, describing unauthorized sensor modifications and increased inaccuracy risk.
- Hunterbrook’s September 18, 2025 report, cited by plaintiffs, alleges hospitalizations and deaths tied to inaccurate G7 readings, which the lawsuits say heightened investor losses.